Skip to main content
. 2018 Dec 11;18:316. doi: 10.1186/s12886-018-0978-9

Fig. 2.

Fig. 2

Endothelial cell density (mm2) before (blue) and after (red) incubation with ranibizumab (Lucentis®) or bevacizumab (Avastin®)